Loading stock data…
GSK PLC ORD 31 1/4P (GSK.L)
LSE1,983pGBX-0.50p (-0.03%)
Market ClosedLast close Jun 26
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GSK plc in the Healthcare sector is trading at 1,983p with a market capitalization of $78.6B. Wall Street consensus targets 2,087p (19 analysts), implying a +5.2% move over the next 12 months. The stock is currently 13% below its 52-week high of 2,282p, remaining 5.5% above its 200-day moving average. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (GBP) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | £7.52B↓ | £7.99B↓ | £8.55B↓ | £8.62B↑ | £7.63B |
| Gross Profit | £5.58B↓ | £5.82B↓ | £6.29B↑ | £5.96B↑ | £5.75B |
| Operating Income | £2.22B↑ | £2.02B↓ | £2.59B↑ | £1.51B↓ | £2.29B |
| Net Income | £1.62B↑ | £1.44B↓ | £2.01B↑ | £636.00M↓ | £1.74B |
Peer Comparison
JNJUNHPFE
Fundamentals
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It oper...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
£78.57B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.80
Beta
Defensive asset. Lower volatility than the S&P 500.
0.29
Div Yield
Strong income play. Yield provides a meaningful total return floor.
354.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
40.91%
Volume
Today's trading volume
13.84M
Recent News
GSK (LSE:GSK) Wins FDA Approval For Utebzi As Momelotinib Gains Orphan Tag
GSK (LSE:GSK) and Spero Therapeutics received U.S. FDA approval for Utebzi, a first in class oral carbapenem antibiotic for complicated urinary tract infections. Utebzi offers an oral treatment option where patients have often relied on intravenous antibiotics for multi drug resistant infections. The U.S. FDA also granted Orphan Drug Designation to GSK's momelotinib for treating VEXAS syndrome, a rare blood disorder. For investors tracking GSK, these two regulatory milestones highlight the...
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition.
Is GSK plc (GSK) Expanding Its Anti-Infectives Leadership With New FDA-Approved Therapy?
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. GSK plc (NYSE:GSK) is one of the best weight loss drugs on this list. TheFly reported on June 17 that GSK and Spero Therapeutics announced that the U.S. Food and Drug Administration approved Utebzi for the treatment of complicated urinary tract infections, including […]
Top Analyst Reports for Micron Technology, Coca-Cola & Arista Networks
MU, KO and ANET headline Zacks' latest analyst reports, with AI demand, pricing gains and networking expansion driving the outlook.
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.